<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068718</url>
  </required_header>
  <id_info>
    <org_study_id>1803.00</org_study_id>
    <secondary_id>NCI-2010-00163</secondary_id>
    <secondary_id>1803.00</secondary_id>
    <secondary_id>P01CA078902</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00068718</nct_id>
  </id_info>
  <brief_title>Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant</brief_title>
  <official_title>Donor Lymphocyte Infusion for the Treatment of Malignancy After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning - A Multi-center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how
      well it works in treating patients with persistent, relapsed (disease that has returned), or
      progressing cancer after donor hematopoietic cell transplantation. White blood cells from
      donors may be able to kill cancer cells in patients with cancer that has come back
      (recurrent) after a donor hematopoietic cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the safety of donor lymphocyte infusion (DLI) as adoptive immunotherapy for
      persistent or relapsed malignant diseases in patients after related or unrelated
      nonmyeloablative transplantation.

      SECONDARY OBJECTIVES:

      I. To determine disease response, progression free and overall survival, chimerism, grade of
      graft-versus-host disease (GVHD), and infections.

      OUTLINE:

      Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo
      restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant
      GVHD develops and disease status worsens or after at least 8 weeks if disease status is
      unchanged and persistent donor T-cells are documented.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD</measure>
    <time_frame>100 days after DLI</time_frame>
    <description>Percentage of Participants with Grade IV Acute GVHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Graft Rejection</measure>
    <time_frame>100 days after DLI</time_frame>
    <description>Percentage patients with graft rejection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Relapse/Progression</measure>
    <time_frame>1 year after DLI</time_frame>
    <description>CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever &gt;38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes &gt;20%.
CMML, AML, ALL &gt;30% BM blasts w/ deteriorating performance status, or worsening of anemia, neutropenia, or thrombocytopenia.
CLL ≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.
NHL &gt;25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.
MM
≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade II-IV GVHD in Patients Undergoing DLI Following a Non-myeloablative Transplant</measure>
    <time_frame>100 days after DLI</time_frame>
    <description>Percentage of Participants with II-IV Acute GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Infections in Patients Undergoing DLI Following a Non-myeloablative Transplant</measure>
    <time_frame>100 days after DLI</time_frame>
    <description>Percentage of Participants with infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year after DLI</time_frame>
    <description>Percentage patients surviving 1 year post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>1 year after DLI</time_frame>
    <description>Percentage of patients with progression-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment (DLI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Therapeutic Allogeneic Lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (DLI)</arm_group_label>
    <other_name>Allogeneic Lymphocytes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only patients having received a preceding nonmyeloablative allogeneic transplantation
             with fludarabine/2 Gy total-body irradiation (TBI) - 4 Gy TBI or 2 Gy TBI - 4 Gy TBI
             conditioning from either a related or unrelated donor are eligible for this protocol

          -  Patients with persistent, relapsed or progressing malignancy after nonmyeloablative
             allogeneic transplantation; persistent disease will be defined as a failure to achieve
             a response as compared to baseline

          -  Patients with rapidly progressing malignancies (acute myeloid leukemia [AML], acute
             lymphocytic leukemia [ALL], blastic phase chronic myelogenous leukemia [CML-BC]
             intermediate-high-grade non-Hodgkin lymphoma [NHL], Hodgkin's lymphoma or aggressive
             multiple myeloma [MM]) should receive salvage chemotherapy or radiation before DLI
             according to the recommendation made in this protocol; any form of salvage
             chemotherapy should be discontinued no less than 3 weeks before DLI; therapy with
             Gleevec or interferon (IFN)-alpha should be discontinued prior to DLI; after salvage
             chemotherapy restaging is performed, patients with progressive disease and patients
             not meeting the inclusion criteria of the study after chemotherapy will be excluded
             from the study; patients are allowed to receive further doses of chemotherapy after
             DLI administration if they are scheduled for further DLI; after additional therapy the
             patients must be restaged and must again meet inclusion criteria to receive further
             DLI

          -  Patients must be able to tolerate a taper of systemic steroids to a dosage of less
             than or equal to 0.25 mg/kg/day; all other immunosuppressive therapy must have been
             discontinued for at least two weeks without significant flares in GVHD (i.e., increase
             of acute GVHD by one or more grades)

          -  Patients must have persistent donor cluster of differentiation (CD)3 cells (&gt; 5% donor
             CD3 cells by a deoxyribonucleic acid [DNA]-based assay that compares the profile of
             amplified fragment length polymorphisms [ampFLP] [or fluorescent in situ hybridization
             (FISH) studies or variable number tandem repeat (VNTR)])

          -  DONOR: Alternatively to a fresh unmodified leukapheresis product, previously collected
             cryopreserved peripheral blood stem cells (PBSC) after mobilization with granulocyte
             colony-stimulating factor (G-CSF) or cryopreserved unmodified leukapheresis product
             from the original donor can be used; if cryopreserved product is not available, the
             DLI product must be from the original donor of hematopoietic cell transplantation

          -  DONOR: Original donor of hematopoietic cell transplantation

          -  DONOR: Donor must give consent to leukapheresis

          -  DONOR: Donor must have adequate veins for leukapheresis or agree to placement of
             central venous catheter (femoral or subclavian)

          -  DONOR: Donor must be medically fit to undergo the apheresis procedure (institutional
             guidelines for apheresis)

        Exclusion Criteria:

          -  Current grade II to IV acute GVHD or extensive chronic GVHD

          -  Karnofsky score &lt; 50%

          -  Lansky Play-Performance Score &lt; 40 for pediatric patients

          -  DONOR: Donors who are not suitable for medical reasons to donate peripheral blood
             mononuclear cells (PBMC) by continuous centrifugation according to the criteria of the
             American Association of Blood Banks (AABB)

          -  DONOR: Pregnancy

          -  DONOR: Human immunodeficiency virus (HIV) or human T-lymphotrophic virus (HTLV)
             infection

          -  DONOR: Recent immunization may require a delay
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Sandmaier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <results_first_submitted>January 20, 2017</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Brenda Sandmaier</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (DLI)</title>
          <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (DLI)</title>
          <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" lower_limit="21" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD</title>
        <description>Percentage of Participants with Grade IV Acute GVHD</description>
        <time_frame>100 days after DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (DLI)</title>
            <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD</title>
          <description>Percentage of Participants with Grade IV Acute GVHD</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Graft Rejection</title>
        <description>Percentage patients with graft rejection.</description>
        <time_frame>100 days after DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (DLI)</title>
            <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Graft Rejection</title>
          <description>Percentage patients with graft rejection.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Relapse/Progression</title>
        <description>CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever &gt;38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes &gt;20%.
CMML, AML, ALL &gt;30% BM blasts w/ deteriorating performance status, or worsening of anemia, neutropenia, or thrombocytopenia.
CLL ≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter’s transformation.
NHL &gt;25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.
MM
≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions.</description>
        <time_frame>1 year after DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (DLI)</title>
            <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Relapse/Progression</title>
          <description>CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever &gt;38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes &gt;20%.
CMML, AML, ALL &gt;30% BM blasts w/ deteriorating performance status, or worsening of anemia, neutropenia, or thrombocytopenia.
CLL ≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter’s transformation.
NHL &gt;25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.
MM
≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade II-IV GVHD in Patients Undergoing DLI Following a Non-myeloablative Transplant</title>
        <description>Percentage of Participants with II-IV Acute GVHD</description>
        <time_frame>100 days after DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (DLI)</title>
            <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade II-IV GVHD in Patients Undergoing DLI Following a Non-myeloablative Transplant</title>
          <description>Percentage of Participants with II-IV Acute GVHD</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Infections in Patients Undergoing DLI Following a Non-myeloablative Transplant</title>
        <description>Percentage of Participants with infections.</description>
        <time_frame>100 days after DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (DLI)</title>
            <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Infections in Patients Undergoing DLI Following a Non-myeloablative Transplant</title>
          <description>Percentage of Participants with infections.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Percentage patients surviving 1 year post-transplant.</description>
        <time_frame>1 year after DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (DLI)</title>
            <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Percentage patients surviving 1 year post-transplant.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Percentage of patients with progression-free survival</description>
        <time_frame>1 year after DLI</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (DLI)</title>
            <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Percentage of patients with progression-free survival</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: Conditioning through Day 100; SAEs: Conditioning through Day 200</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (DLI)</title>
          <description>Patients undergo unirradiated DLI over 15-30 minutes on day 0. Patients then undergo restaging on day 28 and may undergo a second DLI after at least 4 weeks if no significant GVHD develops and disease status worsens or after at least 8 weeks if disease status is unchanged and persistent donor T-cells are documented.
Therapeutic Allogeneic Lymphocytes: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GVHD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Spleen disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Ileal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GVHD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other (Elevated tacrolimus level)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic, and mediastrinal disorders - Other (Unknown)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brenda M. Sandmaier</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>(206) 667-4961</phone>
      <email>bsandmai@fhcrc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

